%0 Case Reports
%T Pemphigus Foliaceus-Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report.
%A Kraft M
%A Worm M
%J Front Med (Lausanne)
%V 5
%N 0
%D 2018
%M 30474029
%F 5.058
%R 10.3389/fmed.2018.00315
%X Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies directed against desmoglein-1 located in the upper epidermal layer. Rituximab, a monoclonal anit-CD20 antibody depleting b-cells, offers an effective treatment possibility for therapy-resistant pemphigus foliaceus. Here, we present the case of 55-year-old man who did not respond sufficiently to conventional treatment with prednisolone, azathioprine, and cyclophosphamide, but underwent almost complete remission after rituximab treatment. The patient relapsed 7 years later, and a repeated course of rituximab infusions led to a partial remission.